Alexandra Toohey
@Baker Bros. Advisors Lp
Latest period2024 - Q3ReportedManaged Assets$9.649BTotal holdings93
Assets growth rate23.31%Assets growth rate (2-Q avg)10.74%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Baker Bros. Advisors Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 93 positions.
Assets under management
The assets under management (AUM) of Baker Bros. Advisors Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 9.649B in assets, with a quarterly growth rate of 23.31% and a 2-quarter average growth rate of 10.74%. The portfolio is managed by Alexandra Toohey, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
EWTXEdgewise Therapeutics, Inc.
| 1.62% | $155.871M 5.84M shares@ $26.7 avg price | |
REPLReplimune Group, Inc.
| 1.26% | $121.057M 11.045M shares@ $10.97 avg price | Increased 9.96% |
ALKSAlkermes Plc
| 1.22% | $117.047M 4.182M shares@ $27.99 avg price | |
DNLIDenali Therapeutics Inc.
| 1.13% | $108.704M 3.732M shares@ $29.13 avg price | |
4576⤦Insmed Incorporated
| 1.02% | $98.325M 42.85M shares@ $2.3 avg price | |
RAREUltragenyx Pharmaceutical Inc.
| 0.91% | $87.553M 1.576M shares@ $55.56 avg price | Increased 7.48% |
NRIXNurix Therapeutics, Inc.
| 0.91% | $87.231M 3.882M shares@ $22.48 avg price | |
TRDAEntrada Therapeutics, Inc.
| 0.81% | $77.756M 4.866M shares@ $15.99 avg price | |
IMTXImmatics N.v.
| 0.77% | $73.519M 6.443M shares@ $11.41 avg price | |
ABCLAbcellera Biologics Inc.
| 0.75% | $71.567M 27.526M shares@ $2.6 avg price |